Treatment of Thrombosis by Sequential Therapy with Ancrod Followed by Streptokinase Clinical Pharmacology and Rheology

Abstract

The effects of sequential therapy with ancrod followed by streptokinase are reported in a series of patients with thrombotic disease. Measurements have been made in blood coagulation, fibrinolysis and whole blood and plasma viscosity. Intravenous infusion of ancrod resulted in a significant reduction in plasma fibrinogen which was associated with highly significant reduction in both plasma and whole blood viscosity. Sequential therapy with streptokinase resulted in a gradual rise in fibrinogen and a slight but significant rise in whole blood and plasma viscosity. All patients showed clinical improvement and no haemorrhagic complications resulted.

Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions

“…May 2017 57 Fiessinger, 1975 58 Fiessinger, 1976 59 Fiessinger, 1977 60 Fiessinger, 1981 61 Fletcher, 1986 62 * Flora, 1970 63 * Forbes, 1976 64 Gaffney, 1984 65 * Gardiner, 1986 66 Gardiner, 1989 67 Goodman, 1993 68 * Graor, 1984 69 Graor, 1985 70 Graor, 1986 71 Graor, 1986 72 Graor, 1988 73 Graor, 1990 74 Gurll, 1976 75 Hallett, 1983 76 Han, 2010 77 Hargrove, 1982 78 Hargrove, 1982 79 Hess, 1982 80 Hess, 1987 81 Hess, 1996 82 Holden, 1990 83 * Huettl, 1995 84 Jorgensen, 1991 85 * Kakkasseril, 1985 86 Katzen, 1981 87 Katzen, 1984 88 Koltun, 1987 89 Kroger, 2000 90 Krupski, 1989 91 Kuss, 2003 92 * Kwaan, 1973 93 * Lammer, 1985 94 Lammer, 1986 95 Law, 1994 96 LeBlang, 1992 97 LeVeen, 1972 98 Lonsdale, 1992 99 Lonsdale, 1993 100 Lucey, 1983 101 * Magnan, 1994 102 Maksimenko, 1999 103 * Marbet, 1982 104 Marder, 1967 105 *…”

Theoretic and Practical Considerations on Laboratory Monitoring of Thrombolytic Therapy

“…To avoid the anticoagulant effect of FDPs, some investigators proposed to administer a defibrinating agent, ancrod, prior to infusion of the thrombolytic agent. 73 However, the resulting delay in the initia tion of thrombolysis is considered as unacceptable in acute situations, such as myocardial infarction.…”